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Abstract
Background: We have recently reported that serotonin4 (5-HT4) receptor agonists have a promising potential as fast-acting
antidepressants. Here, we assess the extent to which this property may be optimized by the concomitant use of
conventional antidepressants.
Methodology/Principal Findings: We found that, in acute conditions, the 5-HT4 agonist prucalopride was able to
counteract the inhibitory effect of the selective serotonin reuptake inhibitors (SSRI) fluvoxamine and citalopram on 5-HT
neuron impulse flow, in Dorsal Raphe ´ Nucleus (DRN) cells selected for their high (.1.8 Hz) basal discharge. The co-
administration of both prucalopride and RS 67333 with citalopram for 3 days elicited an enhancement of DRN 5-HT neuron
average firing rate, very similar to what was observed with either 5-HT4 agonist alone. At the postsynaptic level, this
translated into the manifestation of a tonus on hippocampal postsynaptic 5-HT1A receptors, that was two to three times
stronger when the 5-HT4 agonist was combined with citalopram. Similarly, co-administration of citalopram synergistically
potentiated the enhancing effect of RS 67333 on CREB protein phosphorylation within the hippocampus. Finally, in the
Forced Swimming Test, the combination of RS 67333 with various SSRIs (fluvoxamine, citalopram and fluoxetine) was more
effective to reduce time of immobility than the separate administration of each compound.
Conclusions/Significance: These findings strongly suggest that the adjunction of an SSRI to a 5-HT4 agonist may help to
optimize the fast-acting antidepressant efficacy of the latter.
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Introduction
The recourse to bi-, tri- or even multi-therapy is not uncommon
in current clinical practice. Obviously, one of the most illustrative
examples resides in how ‘‘the tri-therapy’’ has become popular to
treat AIDS patients. In the psychiatric field, though, the use of
multi-therapy as a first line treatment for a single affection is far
from being a systematic option. It is true that many ‘‘atypical’’
antipsychotics have been developed to bind several sites within
the brain. However, as pinpointed by Kapur and Remington in
1996 [1], these molecules have, by definition, a fixed ratio of
affinities for their different targets, and, unlike a cocktail of distinct
active principles, do not permit to modulate each of them in an
independent manner. To define such a strategy as a ‘‘multi-
therapy’’ would therefore appear abusive, if not inappropriate.
Similarly, none of the antidepressant treatments that have been
routinely used so far are based on a bi-(or multi-)therapy concept.
Interestingly, recent in vivo studies, using a wide dose-range, suggest
that even the ‘‘mixed’’ (i.e. with a fixed ratio of affinities) serotonin
(5-HT) and norepinephrine (NE) reuptake blockers venlafaxine and
duloxetine act mostly as selective serotonin reuptake inhibitors
(SSRIs) after systemic administration [2]. Although the adjunction
of atypical antipsychotics to antidepressants may have a therapeutic
interest in some depressed patients [3-4], this combination remains
a second-line solution, used only after the more ‘‘classical’’
molecules have revealed ineffective [4–5]. In addition, the rationale
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9253for this strategy, as well as the underlying biological mechanism(s),
remains to be determined [4–5].
Yet, a dual approach, involving distinct and independent actions
within the brain, might reveal of high interest in the context of
depression. Indeed, the main challenge posed by current treatments
resides in their delayed onset of action, the therapeutic improve-
ment being observable only after 4 to 8 weeks of continuous
administration [6–8]. According to the ‘‘serotonergic theory’’ of
depression, this delay is relatedto the presenceof inhibitory5-HT1A
autoreceptors on 5-HT cell bodies [9–10]. These autoreceptors
actually trigger a strong inhibition of 5-HT neuron firing rate,
counteracting almost totally the passive elevation of 5-HT
extracellular levels that the above cited molecules induce by
blocking the inactivation(catabolismor re-uptake) ofthe transmitter
[9–10]. It is believed that the latency of classical antidepressants
corresponds precisely to the period required for 5-HT1A auto-
receptors to become desensitized [7,9–10]. Based on these
considerations, it has been proposed that one possibility to reduce
the delayed onset of antidepressant action would reside in a direct
activation of 5-HT neuron firing rate, bypassing the presynaptic
5-HT1A control [6,11]. In this context, we have recently reported
that 5-HT4 receptoragonistscaninducesuchanactivation[12–13],
and that they actually may constitute a novel, fast-acting class of
antidepressants [14]. However, the question whether it would be
possible to combine a direct enhancement of 5-HT neuronal
impulse flow with the passive augmentation of 5-HT levels
produced by conventional antidepressants still remainsunanswered.
Indeed, it appears reasonable to expect that such a double action
should produce an optimal increase of the central 5-HT
transmission. Given the apparent importance of this parameter in
antidepressant efficacy [15], this might constitute a significant
breakthrough for patients, as more than 60% of them fail to
respond, or only partially do, to classical treatments [16].
The present study was conducted to assess the ability of various
SSRIs to augment the effect of the selective 5-HT4 agonists
prucalopride and RS 67333, in several experimental paradigms
considered to reflect an antidepressant action. Thus, the chosen
protocols were focused on the study of central 5-HT transmission,
at both the pre- and postsynaptic levels, on the phosphorylation of
the cAMP-response element binding (CREB) protein within the
hippocampus, as well as on the response to several combined
treatments in the forced swimming test (FST) [14].
Results
Effect of acute co-administrations of an SSRI and of the
selective 5-HT4 agonist prucalopride on DRN 5-HT
neuronal firing rate
In all the recorded cells, the intravenous injection of either
fluvoxamine (350 mg/kg, n=10) or citalopram (500 mg/kg, n=11)
strongly reduced 5-HT neuron impulse flow. An illustration of this
effect is shown in Figs. 1A and 1B, showing a decrease to 26% and
Figure 1. Effect of an acute administration of the 5-HT4 agonist prucalopride (1000 mg/kg, i.v.) on the inhibition of DRN 5-HT
neuron firing rate induced by the SSRIs fluvoxamine and citalopram. A and B: Summary of the results found with fluvoxamine (FLVX;
350 mg/kg, i.v.) and citalopram (CIT; 500 mg/kg, i.v.), respectively. Bar histograms represent the mean (6 S.E.M.) percentage effect, calculated for each
neuron with respect to its basal firing rate (i.e., 100% level), and the value at the bottom of each column indicates the number of neurons tested. Only
one single neuron was recorded per animal. * p,0.05 and *** p,0.001 vs basal, + p,0.05 vs fluvoxamine, ## p,0.01 vs citalopram, Tukey’s test.
Panels C and D show individual examples of integrated firing rate histograms, in the cases of a fluvoxamine and a citalopram administration,
respectively.
doi:10.1371/journal.pone.0009253.g001
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citalopram, respectively. Similar results, thought to reflect the
increased stimulation of somatodendritic 5-HT1A autoreceptors
that follows 5-HT reuptake blockade [17–18], have already been
reported when using these SSRIs [18–20]. At difference with what
was observed with SSRIs, two distinct populations of 5-HT
neurons were found regarding their response to subsequent
injection of the 5-HT4 agonist prucalopride (1000 mg/kg, i.v.).
Indeed, in cells specifically chosen for their low (#1 Hz) basal
firing rate, the 5-HT4 agonist was unable to affect the inhibitory
action of either compound (n=5 each, not shown). In contrast,
when 5-HT neurons were selected on the basis of a high ($2 Hz)
basal discharge, prucalopride counteracted the effect of both
fluvoxamine (n=5) and citalopram (n=6) (Figs. 1C and 1D). The
observation of such a dichotomy is in well agreement with our
previous study, describing the existence of a sub-population of
DRN 5-HT neurons ‘‘responding’’ to 5-HT4 receptor stimulation
(47%), the other ones remaining insensitive and having been
dubbed as ‘‘non-responders’’ [12]. In addition, the mean basal
firing activity of responders has been reported to be significantly
higher than that of non-responders [12], which precisely explains
why we chose in the present study to discriminate neurons of
interest on the basis of this same parameter (see also Discussion).
On average, 5-HT neuron impulse flow recovered up to 70%
and 61% with respect to basal values, in the presence of
fluvoxamine and citalopram respectively, after the administration
of prucalopride (Figs. 1A and 1B). Statistically, the recovery
appeared to be total in the case of fluvoxamine [within-design one-
way ANOVA, F(2, 14)=15.9, p,0.001; fluvoxamine alone vs
basal p,0.001, fluvoxamine+prucalopride vs fluvoxamine alone
p,0.05, fluvoxamine+prucalopride vs basal n.s. (Tukey’s test);
Fig. 1A], whereas it was only partial in the case of citalopram, in
that the firing rate observed after prucalopride was still
significantly lower than basal levels [within-design one-way
ANOVA, F(2, 17)=20.6, p,0.001; citalopram alone vs basal
p,0.001, citalopram+prucalopride vs citalopram alone p,0.05,
but citalopram+prucalopride vs basal p,0.05 (Tukey’s test);
Fig. 1B].
Effect of acute co-administrations of citalopram and of
the selective 5-HT4 agonist prucalopride on hippocampal
pyramidal neuron activity
It had previously been reported that in acute conditions, the dose
of a given SSRI required to observe an inhibition of hippocampal
pyramidal neurons is at least 5 to 10 times higher than that able to
suppress the activity of DRN 5-HT neurons [21]. This difference is
thought to be related to the fact that, at lower doses, 5-HT reuptake
blockade concerns essentially the somatodendritic area, hence the
suppression of firing, and that only a massive occupationof terminal
sites produced by a high dose of the SSRI can elicit an elevation of
extracellular 5-HT levels consistent enough to stimulate the
inhibitory hippocampal 5-HT1A postsynaptic receptors [21–22].
Based on this, we used citalopram at 500 mg/kg, i.v. This dose
actually corresponds to no more than 3–4 times the ED50 we
previously found for this drug, regarding its abolishing action on
5-HT neuron activity [14]. Not surprisingly therefore, and as shown
in Fig. 2A, this treatment remained devoid of any effect in all the
9 neurons recorded. The picture, however, was different when
citalopram was administered a few minutes after an intravenous
dose of 1000 mg/kg of prucalopride. In well agreement with the
data reported in our previous study [14], this treatment induced on
its own a 42% reduction of pyramidal neuron activity in 6 of the 15
cells tested (Fig. 2B), whereas the remaining ones were not affected
(not shown). And, in all neurons responding to prucalopride
administration, the subsequent injection of citalopram further
inhibited the firing frequency, which diminished by 62% with
respect to basal values (Fig. 2B) [within-design one-way ANOVA,
F(2, 17)=169.3, p,0.001; prucalopride vs pre-drug and prucalo-
pride+citalopram vs pre-drug p,0.001 each, prucalopride+citalo-
pram vs prucalopride p,0.05, Tukey’s test]. An example of this is
shown in Fig.2C, further illustrating the combined action of the two
drugs in one single pyramidal neuron.
Effect of chronic co-administrations of citalopram with a
selective 5-HT4 receptor agonist on DRN 5-HT mean
neuronal firing rate
In keeping with earlier results from our laboratory [13,23], basal
mean discharge of DRN 5-HT neurons in control (vehicle + vehicle)
animalswasfoundtobe1.1460.1 Hz(Figs.3Aand3B).Overall,the
different chronic treatments (and combinations thereof) tested
significantly modified this value [between-design one-way ANOVA,
F(5, 290)=9.6, p,0.001]. Thus, a 3-day continuous administra-
tion of citalopram (10 mg/kg/d) resulted in a dramatic decrease of
5-HT neuron activity, whichdropped to 31%with respect to control
levels (0.3560.04 Hz) (Tukey’s test, p,0.001 vs vehicle+vehicle;
Fig. 3B). Virtually none of the 5-HT neurons recorded in the
citalopram+vehicle group discharged above 0.5 Hz, whereas it
was common to observe frequencies within the 1–1.7 Hz range in
the vehicle+vehicle one (Fig. 3A). The number of spontaneously
active 5-HT cells was also slightly, but significantly lower in
citalopram-treated than in control rats (Table 1). By contrast, and in
agreement with our previous report [13], both prucalopride
(2.5 mg/kg/d) and RS 67333 (1.5 mg/kg/d) enhanced DRN 5-
HT neuronal activity when they were continuously administered for
3days.Theresultsobtainedhereinareindeedverysimilartothoseof
the 2005 study, with mean values of 1.7360.17 (+52%) and
2.1660.32 Hz (+89%) for prucalopride and RS 67333, respectively
(Tukey’s test, p,0.01 and p,0.001 vs vehicle+vehicle, respectively;
Fig. 3B). On their own, neither of the two 5-HT4 receptor agonists
did affect the number of spontaneously active 5-HT cells per track
(Table 1).
Most importantly, we found that a 3-day co-administration of
the SSRI citalopram with a 5-HT4 receptor agonist resulted in an
increase of DRN 5-HT neuron mean firing rate, displaying an
amplitude similar (or even slightly superior) to that induced by
each agonist alone. As illustrated in Fig. 3A, some of the 5-HT
cells encountered along recording tracks displayed frequencies as
high as 3.5 or even 4 Hz in both combination (citalopram +
prucalopride and citalopram + RS 67333) groups. On average, the
citalopram+prucalopride combined treatment enhanced 5-HT
impulse flow by 65%, and the citalopram + RS 67333 one by
149% (Tukey’s test, p,0.01 and p,0.001 vs vehicle + vehicle,
respectively). Although this latter value appeared to be more
consistent than the +89% effect elicited by RS 67333 alone, the
two groups did not statistically differ from each other (Tukey’s test,
n.s.). However, both combined treatments significantly reduced
the number of spontaneously active cells found per track, to about
one-half with respect to control levels (Table 1).
Effects of chronic co-administrations of citalopram and of
a selective 5-HT4 receptor agonist on the reactivity of
hippocampal pyramidal neurons to 5-HT1A receptor
blockade
The effects of chronic combined treatments were assessed on
the responsiveness of hippocampal pyramidal neurons to systemic
injection of the selective 5-HT1A antagonist WAY 100635. For
this purpose, the compounds of interest were delivered at the
SSRI+5-HT4 Agonist: AD Synergy
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recorded within the CA3 sub-field, before and after cumulative i.v.
doses of WAY 100635. Since most pyramidal neurons are not
spontaneously active under chloral hydrate anaesthesia, the use
of a multi-barreled electrode coupled with microiontophoretic
pumps was required, so that an ejection current of quisqualate
permitted to maintain pyramidal neuron firing rate within the 3–
6 Hz range. These experimental conditions have proved effective
to reveal the manifestation of an inhibitory tonus mediated by
hippocampal postsynaptic 5-HT1A receptors [8], which constitutes
so far a common and selective trait for all chronic antidepressant
treatments [8,24–25].
We previously reported that after only three days of continuous
administration, both prucalopride and RS 67333 are able to
induce the apparition of such a tonus, at difference with
citalopram, which remains inactive within this short time-frame
[14]. As illustrated in Fig. 4, similar results were observed in the
present study, with WAY 100635 displaying a dose-dependent
excitatory effect in rats treated with the 5-HT4 agonists, and being
devoid of any significant effect in both the vehicle/vehicle and
citalopram/vehicle groups. In the presence of prucalopride alone,
cumulative doses of 200 and 300 mg/kg increased the firing
activity of pyramidal neurons to 129620 and 175634% of basal
values, respectively (Fig. 4A); in the vehicle/RS 67333 group, the
enhancement was more pronounced, reaching 128622, 231669
and 316675% after 100, 200 and 300 mg/kg of WAY 100635,
respectively (Fig. 4B). These results are remarkably close to those
reported in our previous study [14]. The adjunction of citalopram
spectacularly potentiated the effect of both 5-HT4 agonists.
Indeed, in citalopram/prucalopride-treated animals, the intrave-
nous administration of WAY 100635 (100, 200 and 300 m/kg)
raised CA3 pyramidal neuron firing rate to 142613, 233640 and
340618% with respect to control levels, respectively (Fig. 4A). In
the citalopram/RS 67333 group, the enhancing action of WAY
100635 reached amplitudes as high as 203614, 357623 and
565668% in the same conditions (Fig. 4B). The ‘‘synergetic’’
nature of these results was further confirmed by the use of two-way
ANOVAs, which revealed the existence of significant interactions
between the citalopram ‘‘pre-treatment’’ and the 5-HT4 agonists
‘‘treatment’’, after the WAY 100635 doses of 300 mg/kg
[pretreatment x treatment interaction, F(1, 15)=7, p,0.05]
(Fig. 4A), and 100 and 300 mg/kg [pretreatment x treatment
interaction, F(1, 15)=4.9, p,0.05, and F(1, 15)=6.3, p,0.05]
(Fig. 4B) in the presence of prucalopride and RS 67333,
respectively. Also noteworthy was the finding that in most cases,
and notably after the highest cumulative dose of WAY 100635,
Tukey’s tests (performed after significant between-designed one-
way ANOVAs) indicated that combination groups were signifi-
Figure 2. Effect of an acute, intravenous administration of citalopram (500 mg/kg), alone or subsequent to an i.v. dose of
prucalopride (1000 mg/kg), on CA3 pyramidal neuron firing activity. A and B: Bar histograms represent the mean (6 S.E.M.) percentage
effect, in the absence or presence of prucalopride respectively, calculated for each neuron with respect to its basal firing rate (i.e. 100% level). The
value at the bottom of each column represents the number of neurons tested (one single neuron recorded per rat). *** p,0.001 vs pre-drug, #
p,0.05 vs prucalopride, Tukey’s test. C: A typical example (integrated firing rate histogram) of the results summarized in B. The neuron chosen to
illustrate this panel is also one of the two cells in which the effect of a local, microiontophoretic application of the selective 5-HT1A antagonist WAY
100635 was tested (see Discussion for details).
doi:10.1371/journal.pone.0009253.g002
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5-HT4 agonists ones (see Figs. 4A and 4B).
Effect of a 3-day combined treatment with the SSRI
citalopram and the 5-HT4 receptor agonist RS 67333 on
CREB phosphorylation in the hippocampus
As illustrated in Fig. 5, a statistical significance was found when
all four groups were compared with a global ANOVA [between-
design one-way ANOVA, F(3, 49)=7.2, p,0.001]. Values in the
citalopram/RS 67333 group were found to be significantly higher
than in both the vehicle/vehicle and vehicle/RS 67333 ones
(Tukey’s test, p,0.001 and p,0.05, respectively), but surprisingly,
in such statistical conditions the difference between vehicle/RS
67333 and vehicle/vehicle did not appear to be significant
(Tukey’s test, n.s.). However, when assessed with a Student’s t-
test, the difference was actually significant (p,0.05, Fig. 5), in
agreement with a recent study from our laboratory showing that a
3-day treatment with RS 67333 alone was sufficient to increase the
pCREB/CREB ratio within the hippocampus [14]. Indeed, and
again, the ratio value found in the present study for the vehicle/RS
Figure 3. Effect of a 3-day co-treatment with citalopram, and either prucalopride or RS 67333, on the mean firing rate of DRN 5-HT
neurons. In each rat, both citalopram (or its vehicle) and the 5-HT4 agonist (or its vehicle) were administered via osmotic minipumps inserted
subcutaneously, and recordings were performed with the two minipumps still in place. A: Integrated firing rate histogram showing samples of DRN
descents in different experimental groups; indicated doses refer to the total daily dosage. B: Summary of the results: bar histograms represent the
mean (6 S.E.M.) firing activity of 5-HT neurons, calculated on the basis of successive recording tracks performed along the DRN. Values at the bottom
of each column indicates the total number of neurons recorded per group (vehicle-vehicle: n=7 animals, citalopram-RS 67333: n=5 animals, and
n=4 animals in the other groups). ** p,0.01 and *** p,0.001 vs vehicle/vehicle, Tukey’s test.
doi:10.1371/journal.pone.0009253.g003
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‘‘RS 67333 group’’ in this previous work (0.3760.02; [14]). Still,
because present control ratios are on average slightly more
elevated, the effect of RS 67333 appears to be less prominent
(+44%, vs +105% in [14]), which is likely to explain why the
Tukey’s test did not reveal a statistical significance after a global
ANOVA.
In the presence of citalopram, RS 67333 was still able to
augment phosphorylation of hippocampal CREB (citalopram/RS
67333 vs citalopram/vehicle p,0.05, Student’s t-test; Fig. 5).
More interestingly, the facilitatory action of RS 67333 was actually
significantly potentiated by the SSRI. Thus, citalopram ‘‘pre-
treatment’’ significantly interacted with RS 67333 ‘‘treatment’’, as
demonstrated by the use of a two-way ANOVA [pre-treatment x
treatment interaction, F(1, 49)=3.8, p,0.05]. Citalopram, which,
as already shown [14], remained without effect on its own after 3
days of administration (citalopram/vehicle vs vehicle/vehicle, n.s.,
Student’s t-test), exerts therefore a synergetic action on the rapid
facilitatory effect of RS 67333. This conclusion is supported by the
significant result of the Student’s t-test used to compare the two
groups of animals treated with RS 67333 (citalopram/RS 67333 vs
vehicle/RS 67333, p,0.05; Fig. 5), which also confirmed the
Tukey’s test mentioned above.
Effects of co-administrations of the 5-HT4 agonist RS
67333 with various SSRIs in the FST
As shown in Fig. 6, the effect of RS 67333 on time of immobility
was, to the lesser, additive with that of fluvoxamine, citalopram
and fluoxetine. More specifically, the between-design one-way
ANOVA was significant in all three experiments [Fig. 6A,
F(3, 33)=7.5; Fig. 6B, F(3, 33)=18.9; Fig. 6C, F(3, 33)=34.9;
p,0.001 for all]. The effect of fluvoxamine alone (221%) failed to
reach statistical significance (Tukey’s test, n.s.), at difference with
that of RS 67333 (238% with respect to this control group,
p,0.05, Tukey’s test) (Fig. 6A). When combined together, these
compounds reduced time of immobility by 55% with respect to the
vehicle/vehicle group (p,0.001, Tukey’s test, Fig. 6A); this value
is, obviously, very close to 59%, which would theoretically
correspond to the sum of individual influences of each drug.
Citalopram induced on its own a significant reduction of time of
immobility (232%, p,0.05 vs vehicle/vehicle, Tukey’s test,
Fig. 6B). In this experiment, the effect of RS 67333 appeared
slightly more pronounced (248%, p,0.001 vs vehicle/vehicle,
Tukey’s test, Fig. 6B), because the control group displayed values
somewhat higher than those of Fig. 6A (91.468.6 s vs 76.468.7 s).
However, in this case also, the co-administration of RS 67333 with
the SSRI resulted in an effect (272%, p,0.001 vs vehicle/vehicle,
Tukey’s test, Fig. 6B), which amplitude was almost similar to the
sum of the two other ones. Interestingly, the citalopram/RS 67333
and citalopram/vehicle groups were statistically different from
each other (p,0.01, Tukey’s test, Fig. 6B), and that was also
almost the case concerning citalopram/RS 67333- and vehicle/
RS 67333-treated animals (p=0.09, Tukey’s test). The adminis-
tration of fluoxetine had virtually no effect on the time spent
immobile (26%, n.s. vs vehicle/vehicle, Tukey’s test, Fig. 6C). On
the other hand, and similarly to the above results, RS 67333
induced a 50% reduction of this parameter (p,0.001 vs vehicle/
vehicle, Tukey’s test, Fig. 6C). The concomitant administration of
fluoxetine and RS 67333 strongly attenuated time of immobility
(274%, p,0.001 vs vehicle/vehicle, Tukey’s test, Fig. 6C). On
the basis of these latter data, it could have been suggested that
RS 67333 and fluoxetine actually exerted a ‘‘synergetic’’ action,
namely that the drugs potentiated the action of each other rather
than simply having added their potency. To verify this possibility,
we performed a two-way ANOVA, with fluoxetine as the ‘‘pre-
treatment’’ factor, and RS 67333 as the ‘‘treatment’’ factor. The
statistical assessment did not reveal a significant interaction [two-
way ANOVA, pre-treatment x treatment interaction, F(1, 35)=2,
n.s.], ruling out the possibility of a true ‘‘synergy’’ between
fluoxetine and RS 67333 in the FST. However, it remains that this
time, the fluoxetine/RS 67333 group was not only statistically
different from the fluoxetine/vehicle one, but also reached
significance when compared to vehicle/RS 67333-treated animals
(p,0.001 each, Tukey’s test, Fig. 6C).
Discussion
The present study shows that the adjunction of an SSRI to a
5-HT4 agonist strongly potentiates the antidepressant-like proper-
ties of the latter in several electrophysiological, molecular and
behavioral paradigms. Moreover, this combined treatment
displays the same rapidity of action than that observed with the
agonist alone, therefore appearing to constitute a very promising
strategy in a clinical perspective.
As previously reported [18–20], an acute administration of the
SSRIs fluvoxamine and citalopram almost suppressed the activity
of all DRN 5-HT neurons recorded. Because 5-HT4 receptor
agonists have been reported to increase the firing rate of a
subpopulation (47%) of ‘‘responding’’ 5-HT neurons [12], we
tested the ability of a subsequent injection of the selective 5-HT4
agonist prucalopride [26] to reverse the SSRI-induced inhibition.
Responding neurons display a significantly higher average basal
firing rate than that of non-responders [12], and thus, to optimize
the discrimination between the two populations, the 5-HT
neurons selected for recordings had been chosen for discharging
within either the lower (#1 Hz) or the upper ($2 Hz) range of
usual frequencies. We found that prucalopride counteracted the
inhibition induced by both SSRIs in all ‘‘upper-frequency’’ cells,
whereas it remained without any effect in the ‘‘lower-frequency’’
ones. These results confirm, once again [12], that a high basal
firing rate constitutes a good predictor concerning the 5-HT4-
Table 1. Average number (6 S.E.M.) of 5-HT neurons found per recording tracks (‘‘descents’’) performed along the DRN, in rats
treated for three days with citalopram (cit, 10 mg/kg/d), prucalopride (pru, 2.5 mg/kg/d), RS 67333 (RS, 1.5 mg/kg/d) or their
vehicle (veh).
Treatment group
veh/veh cit/veh veh/pru cit/pru veh/RS cit/RS
# of 5-HT neurons per track 4.5460.5 2.7560.7
a 4.1360.6 260.3
c 4.160.8 1.9560.3
c
In each animal, two osmotic minipumps, filled with either a compound of interest or its vehicle, were inserted under the skin of the back under short-duration (,5 min)
anaesthesia. Recordings were performed with the minipumps still in place. a, p,0.05; c, p,0.001 vs veh/veh (Student’s t-test).
doi:10.1371/journal.pone.0009253.t001
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they also strongly suggest that the mechanisms underlying,
respectively the 5-HT4-dependent excitatory control and the
SSRI-induced decrease of 5-HT function, are fully independent
from each other. Indeed, it is now well established that the latter
results from an increased stimulation of 5-HT1A inhibitory
autoreceptors, which itself is consecutive to the strong elevation
of extracellular 5-HT levels that follows 5-HT reuptake blockade
in the somatodendritic area [17–18,20]. It has also been reported
that the firing activity of almost one-half of DRN 5-HT neurons
can be reduced by stimulating some postsynaptic 5-HT1A
receptors, localized within the medial prefrontal cortex (mPFC)
and that trigger a negative ‘‘long-loop feedback’’ [17,27]. How-
ever, this regulatory mechanism does not participate in the
suppressing action of SSRIs, the enhancement of 5-HT outflow
elicited by these drugs being apparently not consistent enough to
permit the stimulation of cortical 5-HT1A receptors [17].
In contrast, the excitatory control exerted by 5-HT4 receptors
on 5-HT neuronal impulse flow does not seem to involve any
presynaptic modulation [13], and has been suggested to originate
from the mPFC through the activation of a positive ‘‘long-loop
feedback’’ [13]. The fact that neither fluvoxamine nor citalopram
could preclude the facilitatory action of prucalopride in respond-
ing neurons suggests, therefore, that the elevation of 5-HT
extracellular levels induced by an SSRI is also not sufficient for
stimulating cortical 5-HT4 receptors. Interestingly, calculating the
difference between the percentages found in the SSRI+prucalo-
pride condition (70% and 61% with respect to basal levels for
fluvoxamine and citalopram, respectively) and in the SSRI alone
one (26% and 18%, respectively) leads to a quasi-constant value
(44% vs 43%), regardless of the SSRI considered. That the effect
of prucalopride remains so remarkably stable in the presence of
two different, structurally unrelated compounds with differential
potencies as 5-HT reuptake blockers [28] further supports the idea
that the 5-HT4-mediated control on 5-HT neurons is independent
from SSRI-triggered mechanism(s) of action. Finally, the facilita-
Figure 4. Effect of the combination of citalopram with a 5-HT4
agonist on the postsynaptic 5-HT1A neurotransmission. Cumu-
lative intravenous doses of the selective 5-HT1A antagonist WAY 100635
were performed in rats continuously treated with A, the citalopram
(10 mg/kg/d) + prucalopride (2.5 mg/kg/d) or B, the citalopram + RS
67333 (1.5 mg/kg/d) combination for three days, and their effects on
the firing activity of hippocampal pyramidal neurons were recorded in
the CA3 sub-field. Single-cell extracellular recordings were performed in
chloral-hydrate anaesthetized animals, by using multiple-barrel glass
microelectrodes combined with microiontophoretic pumps, and results
expressed as the mean (6 S.E.M.) percentage elevation of the firing rate
with respect to pre-drug values (n=4 animals in each group). All
compounds (or their vehicle) were administered through the use of
osmotic minipumps, inserted subcutaneously in the region of the back.
Recordings were performed with the minipumps still in place. * p,0.05,
** p,0.01 and *** p,0.001 vs respective vehicle/vehicle values;
+ p,0.05, ++ p,0.01 and +++ p,0.001 vs respective citalopram/
vehicle values; & p,0.05 and && p,0.01 vs respective vehicle/
prucalopride values; # p,0.05 vs respective vehicle/RS 67333 values
(Tukey’s test). The ‘‘a’’ symbol indicates a p,0.05 significant interaction
between the citalopram ‘‘pre-treatment’’ and the 5-HT4 agonist
‘‘treatment’’, as revealed by the use of a two-way ANOVA.
doi:10.1371/journal.pone.0009253.g004
Figure 5. Effect of the continuous co-administration of
citalopram (10 mg/kg/d) and RS 67333 (1.5 mg/kg/d) for 3
days on pCREB. The activation of CREB in hippocampal tissue was
assessed by measuring phosphoCREB (pCREB) immunoreactivity. CREB
phosphorylation was normalized according to the amount of protein
present in each sample by expressing the data as a ratio of pCREB over
total CREB immunoreactivity. Results represent mean 6 SEM for the
number of experiments indicated, for each treatment, by the value at
the bottom of the column. Inset shows representative examples of
pCREB immunoreactivity for different treatment conditions indicated
on the histogram. All compounds were administered through the use
of osmotic minipumps, inserted subcutaneously in the region of the
back. * p,0,05 vs vehicle/vehicle, + p,0.05 vs citalopram/vehicle and
# p,0.05 vs vehicle/RS 67333, Student’s t-test.
doi:10.1371/journal.pone.0009253.g005
SSRI+5-HT4 Agonist: AD Synergy
PLoS ONE | www.plosone.org 7 February 2010 | Volume 5 | Issue 2 | e9253tory action of 5-HT4 receptor stimulation on 5-HT impulse flow
permitted to unmask the effectiveness of a low dose of citalopram
on postsynaptic targets. The i.v. injection of 500 mg/kg of
citalopram, devoid of any effect on its own, significantly reduced
CA3 pyramidal neuron activity when administered after prucalo-
pride. Usually, such an effect is only observed in the presence of
high doses of SSRIs [21–22], because the elevation of 5-HT
outflow induced by these compounds is a passive phenomenon,
strongly depending on electrical activity [21]. When this
parameter is almost null, a massive occupation of reuptake sites
is therefore required to increase 5-HT transmission at the
postsynaptic level [21–22]. Our results confirm that this is no
more required if 5-HT neuron firing rate becomes ‘‘normalized’’,
as it is the case in the presence of a 5-HT4 agonist. The
postsynaptic 5-HT receptor(s) responsible for this inhibition of
pyramidal neuron firing remains to be characterized, but it is likely
that the 5-HT1A type contributes, at least partially, to its
expression. The effect of a local, microiontophoretic application
of WAY 100635 was tested in two of the 6 responding neurons,
and in both cases, it was actually able to reverse the effect of the
prucalopride+citalopram combination (Fig. 2C).
The picture was slightly different when citalopram was co-
administered continuously for three days with either prucalopride
or RS 67333, an other selective 5-HT4 agonist [29]. In this case,
indeed, the concomitant stimulation of 5-HT4 receptors did not
only counteract the suppressing action of the SSRI, but actually
resulted in an increase of the average DRN 5-HT neuron firing
frequency, which amplitude was comparable to that induced by
each 5-HT4 agonist alone. In our opinion, this finding is likely to
be related to desensitization processes occurring at the level of
somatodendritic 5-HT1A autoreceptors, as the analysis of the
number of spontaneously neurons found per track in the different
experimental groups also indirectly suggests. Thus, in agreement
with earlier studies [30], a 3-day treatment with citalopram alone
strongly reduced (270%) the mean activity of central 5-HT
neurons. It is known that, after such a short duration of treatment,
5-HT1A autoreceptors are still fully functional [9,30]. Conse-
quently, the presence of citalopram results in either a marked
lowering of 5-HT impulse flow, hence the average reduction
mentioned above, or in its total suppression, hence the slight
reduction in the number of active cells found per descent (Table 1)
[9,30]. On the other hand, the continuous administration of a
5-HT4 agonist for three days elicits a desensitization of 5-HT1A
autoreceptors, which concerns apparently both ‘‘responding’’ and
non-responding 5-HT neurons [14]. This is only a partially
achieved process, however, as a stronger activation of autorecep-
tors can still suppress 5-HT neuronal firing rate at this point [14].
Assuming that the summed influences of an SSRI and of a 5-HT4
agonist should result in a massive elevation and diffusion of
extracellular 5-HT within the DRN, this property could account
for the 50% reduction of spontaneously firing cells, observed in
both combined treatment groups (Table 1). Silent neurons would
correspond to the (about) 50% of non-responders, in which by
definition 5-HT4 agonism can not compensate for an activation of
5-HT1A autoreceptors. In the case of responders, it is possible that
the elevation of 5-HT levels is so important in the immediate
vicinity of the somatodendritic region, that their autoreceptors are
this time not partially, but already fully desensitized at day 3 after
the onset of treatment. This would explain the finding that co-
administrations have similar effects than 5-HT4 agonists alone,
and do not simply permit a recovery of 5-HT activity as observed
in acute conditions.
Additional experiments are obviously required to confirm the
above hypotheses, but it it is clear that, whatever the underlying
mechanisms, the facilitatory effect of a 3-day treatment with a 5-
HT4 agonist on the average 5-HT impulse flow is not altered by
the concomitant adjunction of an SSRI. However, because only
one-half of 5-HT neurons are active in such conditions, the
question remains whether these promising ‘‘presynatpic’’ results
can effectively translate into an increased efficacy at the
postsynaptic level. To address this point, we assessed the influence
of a 3-day combined treatment, on the response of hippocampal
pyramidal neurons to an acute injection of the selective 5-HT1A
Figure 6. Effect of RS 67333 (1.5 mg/kg, i.p.), in combination
with various SSRIs, on the time spent immobile in the FST. The
SSRIs used were A fluvoxamine (10 mg/kg, i.p.), B citalopram (10 mg/kg,
i.p.), and C fluoxetine (10 mg/kg, i.p.). All data are expressed as mean 6
S.E.M. of eight animals per group (except for the vehicle/RS 67333 group
which comprises 12 animals), and are from an observation of 4 min
duration. Rats experienced a pre-test session (15 min) 24 h before the
test session. In each animal, RS 67333 (or its vehicle) and the SSRI (or its
vehicle) were administered almost concomitantly (within a 30 s interval),
30 min before the test session; the sites chosen for i.p. injections were
always symmetrically opposed with respect to the abdomen midline.
*p ,0.05 and *** p,0.001 vs vehicle/vehicle, ++ p,0.01 vs citalopram/
vehicle, {{{ p,0.001 vs fluoxetine/vehicle and # p,0.05 vs vehicle/RS
67333, Tukey’s test.
doi:10.1371/journal.pone.0009253.g006
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experimental protocol allows unveiling the manifestation of a
5-HT1A-mediated inhibitory tonus within the hippocampus, a
specific feature induced by all currently used antidepressant
treatments [24]. Indeed, WAY 100635 is virtually devoid of effect
on DRN 5-HT activity in anaesthetized rats [for review, 31], and
any change observed in such conditions is therefore very likely to
reflect postsynaptic events. In agreement with earlier studies [14],
our results indicate that an increased 5-HT1A tone is already
observable after three days of treatment with either prucalopride
or RS 67333. They also show that the concomitant presence of
citalopram does not preclude this effect of 5-HT4 receptor
agonists. This should be regarded as a critical point, the rapidity
of action of the latter in the same experimental paradigm having
constituted one of the rational bases to propose their use as fast-
acting antidepressants [14]. More importantly even, the response
to WAY 100635 was much more pronounced in the case of co-
administrations, indicating the presence of a more consistent 5-HT
tonus. Thus, despite the 50% reduction of spontaneously active
5-HT neurons observed in these conditions, it appears that the
raphe ´-hippocampus transmission was globally optimized. Statisti-
cal analysis of the experiments, using two-way ANOVAs, revealed
that SSRI ‘‘pretreatment’’ interacted significantly with 5-HT4
agonists ‘‘treatments’’, confirming the ‘‘synergetic’’ (i.e more than
additive) nature of the combination. At difference with acute
experiments, in this case the firing activity of 5-HT neurons was
not normalized, but actually facilitated by the presence of 5-HT4
agonists. Considering the above discussed relationship between
efficacy of reuptake blockade and impulse-flow, it is therefore not
surprising that the SSRI displayed a more consistent influence at
the terminal level, and that its effect was not simply added to that
of the agonist. Interestingly, together these results also indirectly
suggest that the efficacy of the combined treatment might improve
over time. Thus, if an incomplete desensitization of 5-HT1A
autoreceptors is actually responsible for the silencing of 50% of
5-HT neurons at day 3 (see above), it is reasonable to expect a
recovery after 2-3 weeks, as observed when citalopram is given
alone [9,30]. The resulting increase of 5-HT transmission would
then be likely to ‘‘sum up’’ with that already triggered by the
combined treatment, and related to ‘‘5-HT4-responding’’ 5-HT
neurons. Indeed, the excitatory effect induced by 5-HT4 agonists
displays a similar amplitude after 3 or 21 days of continuous
administration [13]. Long-term (3 weeks) experiments are
currently underway to confirm this possibility.
That the two classes of compounds have a synergetic action
when chronically administered for three days was confirmed by
assessing their combined influence on CREB activation. We
recently reported that 5-HT4 agonists are already able to increase
the hippocampal pCREB/CREB ratio within such a short time-
frame [14], a property which, again, is typical of classical
antidepressants but requires a prolonged (2–3 weeks) treatment
with these molecules to manifest [32–34]. In the present study,
similarly to what was observed on the 5-HT1A-mediated tonus in
electrophysiological experiments, citalopram had no effect on its
own, but strongly enhanced the efficacy of RS 67333. This
remarkable parallelism of results between the two experimental
paradigms further supports the idea of a direct relationship linking
the raphe ´-hippocampus 5-HT transmission and the mechanisms
triggering CREB activation [35–36]. It also indirectly suggests that
the effect of 5-HT4 agonists on pCREB formation might not result
from a dual action, namely a direct stimulation of the 5-HT4
receptors located on pyramidal neurons in addition to a global
facilitation of 5-HT function, as previously proposed [37]. Indeed,
if it had been the case in the present experimental conditions,
citalopram should have competed with RS 67333 to stimulate
hippocampal 5-HT4 receptors, and consequently to induce the
phosphorylation of CREB. The occurrence of a synergetic action
would have been therefore mostly improbable. Again, this
hypothesis remains to be experimentally confirmed, and lesion/
depletion studies are currently underway in our laboratory to
determine the extent to which hippocampal 5-HT4 receptors are
involved in the facilitatory effect of 5-HT4 agonists on CREB
activation.
Altogether, the above results indicate that a combined SSRI/
5-HT4 agonist treatment displays the same rapidity of action than
the agonist alone to induce electrophysiological and molecular
markers, specific of an antidepressant action. The adjunction of
the SSRI, however, results in a dramatic potentiation of the
markers amplitude, suggesting an even more promising clinical
perspective. ‘‘Augmentation’’ strategies, aimed at helping conven-
tional antidepressants to sustain their actions within the brain,
appear actually to constitute an effective option for the two-thirds
of patients who do not respond (or only partly do) to their
treatment [16]. The improved antidepressant potential of the
combination was further confirmed by the results found in FST
experiments. Although this behavioral test can be performed in
acute conditions, and does not reflect the need for prolonged
treatment, it remains highly reliable to predict the ability of a given
compound to reveal effective as an antidepressant [38]. Our results
clearly show that the effect of RS 67333 was potentiated by a
number of SSRIs, to the lesser in an additive manner, or almost
synergistically in the case of fluoxetine. Again, this pattern was
strikingly similar to what was observed in electrophysiological and
molecular paradigms, strengthening the idea that central 5-HT
neurotransmission plays also a pivotal role in antidepressant-
induced behavioral changes [14–15,36]. Obviously, such impres-
sive effects induced by the SSRI/5-HT4 agonist association on the
5-HT transmission-pCREB-behavior ‘‘continuum’’ strongly sup-
port its use as a bi-therapy strategy for the treatment of depression.
As recently pinpointed [37], there is still a need for safe 5-HT4
agonists able to enter the brain, and acceptable for clinical trials.
Provided this critical step could be achieved however, the amount
of SSRIs already available warranties the possibility to test
multiple combinations, aimed at optimizing therapeutic outputs.
For instance, the fact that a low dose of citalopram is already
effective on postsynaptic targets when co-administered with a
5-HT4 agonist (Fig. 2) opens the perspective of reducing the doses
of SSRI administered, in order to reduce side-effects as well. It is
also of importance to mention that only one dose (1.5 mg/kg) of
RS 67333 has been tested in the present study. It was chosen on
the basis of previous reports, showing robust and consistent
influence on the targeted parameters of interest (5-HT neuron
firing rate, CREB phosphorylation) [13–14]. The fact that the
amplitudes of effect were even higher when the same dose of
compound was combined with SSRIs clearly indicates that, in this
case, the aimed ‘‘augmentation’’ was actually effective. We did
not, however, perform a complete dose-response study to
determine which dose(s) of the 5-HT4 agonist permit(s) to observe
an optimal augmentation. Obviously, such preclinical assessments
will become required once safe, brain penetrant 5-HT4 agonists
will have been designed to conduct clinical trials.
This would constitute one of the first attempts to use a bi-therapy
approach as a first-line solution to treat depression. About 15 years
ago, after a series of cleverly conducted preclinical investigations, the
group led by F. Artigas started to perform clinical tests also based on
a dual administration strategy [39]. The idea consisted of giving the
5-HT1A receptor blocker pindolol concomitantly with a convention-
al antidepressant; because experimental data had suggested that
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thought that such a combination could permit to reduce the delay of
action of the treatment (see Introduction) [39–40]. Unfortunately, it
appears that in humans, pindolol is also able to block significantly
postsynaptic 5-HT1A receptors, especially at the higher doses used
[41–42].Consideringthecrucialroleplayedbythesereceptorsinthe
effect of antidepressants [10,15], itis therefore not surprising that the
different trials conducted led to controversial and variable results,
with no consistent improvement observed concerning the amplitude
of the therapeutic efficacy, and a reduced delay that was not
systemically found [40]. On the other hand, the present results
suggest that the mechanisms of action underlying the potential
antidepressant properties of 5-HT4 receptor agonists and those of
SSRIs do not interfere with each other. It is therefore reasonable to
hope that their combination may constitute in the future one of the
routine bi-therapies used in depressed patients.
Materials and Methods
Animals
Experiments were carried out in male Sprague-Dawley (Charles
River, St-Constant, Que ´bec, Canada, and Harlan, Gannat,
France) rats, weighing 250–300 g and kept under standard
laboratory conditions (12:12 light-dark cycle with free access to
food and water, light starting from 7 AM). Experiments were
performed in conformity with the Canadian Guide to the Care
and Use of Experimental Animals (Vol. 1, 2nd edition, 1993) and
with the guidelines of the French Ministry of Agriculture (87/847,
modified May, 2001). All efforts were made to minimize the
number of animals used in each experimental group.
Drugs and chemicals
The following compounds were used: prucalopride monohy-
drochloride, fluvoxamine maleate, citalopram hydrobromide,
fluoxetine hydrochloride (gifts from Janssen, Solvay, Lundbeck
and Eli Lilly laboratories, respectively), RS 67333 hydrochloride
(Tocris Cookson Inc., Ellisville, MO, USA), WAY 100635
hydrochloride (Research Biochemicals, Natick, MA, USA). All
compounds were diluted in distilled water, and in each case, drug
dosage refers to the free base. All other reagents were the purest
commercially available. For chronic treatments, prucalopride
(2.5 mg/kg/day), RS 67333 (1.5 mg/kg/day), citalopram
(10 mg/kg/day) or the vehicle were delivered through osmotic
minipumps (Alza, Palo Alto, CA, USA), inserted subcutaneously in
the region of the back under short-duration (#5 min) halothane
anaesthesia. Given that these experiments were performed to
assess the effect of the concomitant administration of an SSRI with
a 5-HT4 receptor agonist, in each animal two minipumps,
containing either the compound of interest or its vehicle, were
simultaneously inserted.
Extracellular recordings of DRN 5-HT neurons
Recordings were performed using single-barreled glass micro-
pipettes. Electrodes were filled with a 2 M NaCl solution saturated
with Fast Green FCF, resulting in an impedance of 2–5 MV. Rats
were anaesthetized with chloral hydrate (400 mg/kg, i.p.) and
placed in a stereotaxic frame. A burr hole was drilled on the
midline 1 mm anterior to lambda. DRN 5-HT neurons were
encountered over a distance of 1 mm starting immediately below
the ventral border of the Sylvius aqueduct. These neurons were
identified using the classical criteria: a slow (0.5–2.5 Hz) and
regular firing rate and long-duration (0.8–1.2 ms) positive action
potentials [43]. At the end of the experiments, a 25 mA cathodal
current was passed through the recording electrode to leave a Fast
Green deposit at the recording site. Animals were sacrificed with
an i.v. overdose of chloral hydrate, and the brain removed. The
site of recording was verified under microscope immediately after
experiments. In the case of chronic administrations, recordings
were performed with the two minipumps still in place.
Extracellular recordings from hippocampal CA3
pyramidal neurons and microiontophoresis
Recording and microiontophoresis were performed with five-
barreled glass micropipettes broken back to 8–12 mm under
microscope control. The central barrel was filled with the same
solution as in the DRN and was used for extracellular unitary
recordings. Pyramidal neurons were identified by their large
amplitude (0.5–1.2 mV) and long-duration (0.8–1.2 ms) simple
spikes alternating with complex spike discharges [44]. The side
barrels contained the following solutions: quisqualate (1.5 mM in
200 mM NaCl, pH 8), WAY 100635 (15 mM in 200 mM NaCl,
pH 4), and 2 M NaCl used for automatic current balancing. Rats
were mounted in the stereotaxic apparatus and the micropipettes
were lowered at 4.2 mm lateral and 4.2 anterior to lambda into
the CA3 sub-region of the dorsal hippocampus. In the case of
chronic administrations, recordings were performed with the two
minipumps still in place.
Assessment of CREB and pCREB immunoreactivities
Following decapitation (performed under halothane anaesthe-
sia) rat brains were dissected on ice cold artificial cerebrospinal
fluid (125 mM NaCl, 2.4 mM KCl, 0.83 mM MgCl2, 1.1 mM
CaCl2, 0.5 mM KH2PO4, 0.5 mM NaSO4, 27 mM NaHCO3,
10 mM glucose, 10 mM Hepes, pH 7.4). Isolated hippocampi
(1–2 mg wet tissue/100 ml) were homogenized in solubilization
buffer containing 20 mM Hepes pH 7.9, 0.4 M NaCl, 20% (v/v)
glycerol, 1% (v/v) Nonidet P-40, 5 mM MgCl2, 0.5 mM EDTA,
0.1 mM EGTA, 1 mM phenylmethanesulfonyl fluoride, 1 mM
okadaic acid, 5 mM dithiothreitol, 5 mg/ml leupeptin, 5 mg/ml
soybean trypsin inhibitor, and 10 mg/ml benzamidine by means of
a dounce homogenator. Homogenates were then adjusted to a
concentration of 2 mg protein/ml and incubated on ice for
30 min, after which they were centrifuged for additional 30 min at
15,000 g. The supernatant was discarded and SDS sample buffer
was added to the pellet for posterior immunoblot analysis. For
detection of CREB activation samples were sonicated and then
boiled for 5 min before loading for SDS-PAGE that was
performed as previously described [45] using a 4% stacking gel
and 10% separating gel. Proteins resolved in SDS-PAGE were
then transferred from gels onto nitrocellulose (50 mA, 16 h, Bio-
Rad Mini-Trans Blot apparatus) and pCREB detected by probing
membranes with anti-pCREB monoclonal antibody (1B6) from
Cell Signaling Technology (1:1000). Total CREB contents was
determined after stripping by using 1:1000 dilution of anti-CREB
antibody (Cell Signaling Technology). Secondary antimouse
(1:5000; Sigma) or antirabbit (1:40000; Amersham) horseradish-
conjugated antibodies and enhanced chemiluminescence detection
reagents (NEN Life Science Products) were used to reveal blotted
proteins. Relative intensities of the labeled bands were analyzed by
densitometric scanning using MCID (Imaging Research Inc) and
CREB-activation was expressed as the ratio between pCREB and
total CREB present in each sample.
Forced swimming test
The FST was performed by using a two-sessions procedure
modification of the protocol originally described by Porsolt et al.
[46]. Briefly, rats experienced a pre-test session followed 24 hours
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conducted under low illumination (15 W), the animals were placed
in a plastic cylindrical tank (50 cm high by 20 cm in diameter) filled
with water at 24u61uC, with a depth of 40 cm, for which the hind
limbs could not reach the tank floor. In all experiments, the pre-test
was carried out for 15 min and the test for 5 min in the same tank
butthelast4 minonlywereanalyzed.RS67333(1.5 mg/kg,i.p.)or
its vehicle was administered concomitantly with either fluvoxamine
(10 mg/kg, i.p.), citalopram (10 mg/kg, i.p.), fluoxetine (10 mg/kg,
i.p.) or their vehicle 30 min before the test session. All experiments
were carried out within a single step (i.e. only one pre-test and one
test session have been conducted). Overall, ten (10) experimental
groups have been performed: vehicle + RS 67333, three [SSRI +
vehicle], three [SSRI + RS 67333] and three [vehicle + vehicle]
(control) groups. Following both pre-test and test sessions, rats were
dried with a towel and kept warm for 30 min before returning in
their home cage. A camera coupled with a computer recorded on
line animal behavior during the FST through a specialized digital
interface (Videotrack, ViewPoint, Lyon, France). This interface
underscored on line the subtraction of video frames. Immobility
time in FST was derived from the number of frames (every 40 ms)
being below a predefined threshold over FST duration. This
threshold was preliminarily set up in order to obtain about 95%
of the corresponding frames classified as immobile for a non-
swimming rat in its water tank.
Statistical analysis
All data are expressed as means 6 SEM unless otherwise
specified. The effects of acute administration of prucalopride,
either on the fluvoxamine- and citalopram-induced inhibition of
5-HT neuron activity, or on hippocampal neuron firing rate, were
assessed using a within-design one-way ANOVA, followed by
Tukey’s post hoc test. The difference between the number of
spontaneously active DRN 5-HT neurons found per recording
track in control vs treated animals was evaluated using the
Student’s t-test. A Student’s t-test was also performed to assess the
effect of RS 67333 on hippocampal CREB phosphorylation, either
in the absence or in the presence of citalopram, as well as to
compare the vehicle/RS 67333 group with the citalopram/RS
67333 one (see Results for more details). In other experiments,
differences between groups were assessed using between-design
one-way ANOVAs, followed by post-hoc analysis (Tukey’s test)
when multiple comparisons were necessary. In some cases, two-
way ANOVAs were also used to determine whether pretreatment
(SSRI) interacted with treatment (5-HT4 agonist).
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